Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.37 |
| ▸ | P2RX3 | P56373 | 7/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.33 |
| ▸ | SELE | P16581 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17885963 | 0.89 | KMT2A (0.37) | KMT2AMEN1KDM4CNPC1RAB9A | |
| SCHEMBL17885957 | 0.88 | KMT2A (0.37) | KMT2AMEN1KDM4CNPC1RAB9A | |
| SCHEMBL17885959 | 0.88 | KMT2A (0.37) | KMT2AMEN1KDM4CNPC1RAB9A | |
| SCHEMBL18106026 | 0.84 | NPC1 (0.41) | KMT2AMEN1KDM4CNPC1RAB9A | |
| SCHEMBL23092798 | 0.83 | MEN1 (0.44) | KMT2AMEN1KDM4CNPC1RAB9A | |
| SCHEMBL17027750 | 0.82 | MEN1 (0.38) | KMT2AMEN1KDM4CNPC1RAB9A | |
| SCHEMBL17027729 | 0.82 | MEN1 (0.38) | KMT2AMEN1KDM4CNPC1RAB9A | |
| SCHEMBL17027736 | 0.82 | MEN1 (0.38) | KMT2AMEN1KDM4CNPC1RAB9A | |
| SCHEMBL17868831 | 0.82 | MEN1 (0.38) | KMT2AMEN1KDM4CNPC1RAB9A | |
| SCHEMBL17027824 | 0.82 | MEN1 (0.38) | KMT2AMEN1KDM4CNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160186094-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | MATERIA, INC. | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160186094-A1 | PREPARATION OF SURFACTANTS VIA CROSS-METATHESIS | SMURF2, EPHX2, SMURF1 | KMT2A 2025/4885MEN1 3213/4885IDO1 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.